# US Renal Disease Market

> US Renal Disease Market Research Report By Type (Chronic Kidney Disease, End-Stage Renal Disease), By Treatment (Dialysis, Medication, Kidney Transplantation) and By End User (Dialysis Centers, Hospital & Clinics, Research and Academic Institutes) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.72%
- **2024:** $ 819 Million
- **2025:** $ 898.61 Million
- **2035:** $ 2,272.16 Million
- **Key Players:** Fresenius Medical Care (DE), DaVita Inc (US), Baxter International Inc (US), AbbVie Inc (US), Amgen Inc (US), Novartis AG (CH), Sanofi (FR), Roche Holding AG (CH), Merck & Co Inc (US)

**Report ID:** MRFR/Pharma/18483-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-renal-disease-market-20030

---

## Market Summary

## **US Renal Disease Market Overview**

As per MRFR analysis, the US Renal Disease Market Size was estimated at 756 (USD Million) in 2023. The US Renal Disease Market Industry is expected to grow from 850(USD Million) in 2024 to 2,100 (USD Million) by 2035. The US Renal Disease Market CAGR (growth rate) is expected to be around 8.57% during the forecast period (2025 - 2035).

### **Key US Renal Disease Market Trends Highlighted**

The US Renal Disease Market is currently experiencing several significant trends driven by both demographic and technological factors. One of the key market drivers is the increasing prevalence of renal diseases, particularly due to rising rates of diabetes and hypertension among the US population. As more individuals are diagnosed with chronic kidney disease (CKD), there is a growing demand for effective treatment options, including dialysis and kidney transplants.

This has led to more innovations in treatment modalities, improving patient outcomes and quality of life. Opportunities for growth within the market also emerge from advancements in telemedicine and home-based therapies. Patients are increasingly seeking alternatives to in-clinic treatments, and this trend provides a chance for companies to develop and offer more remote monitoring solutions and home dialysis options.

The shift towards personalized medicine is another noteworthy trend, which allows for treatments tailored to the individual needs of patients based on their unique medical profiles. In recent times, there has been a heightened focus on value-based care and improving patient engagement. Healthcare providers in the US are actively working to enhance patient experience and outcomes, incentivizing better management of renal disease.

Additionally, federal initiatives aimed at improving kidney care, such as the Advancing American Kidney Health initiative, emphasize the significance of early detection and preventive measures, further shaping the market landscape. These trends signify a transformative phase in the US Renal Disease Market, driven by evolving patient needs and innovative solutions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Renal Disease Market Drivers**

### **Increasing Prevalence of Chronic Kidney Disease**

Chronic Kidney Disease (CKD) has become increasingly prevalent across the United States, with nearly 15% of the adult population affected, according to the Centers for Disease Control and Prevention (CDC). This rising incidence is primarily attributed to the growing rates of diabetes and hypertension, which are major risk factors for CKD.

Specifically, the CDC indicates that diabetes is expected to affect approximately 30.3 million individuals in the US by 2035, significantly elevating the demand for effective renal disease management and treatment options. As the US Renal Disease Market Industry faces a higher patient volume, there is a clear impetus for stakeholders to enhance their services and product offerings, leading to market growth.

Moreover, organizations such as the National Kidney Foundation play a crucial role in raising awareness and advocating for better healthcare practices, which further fuels the market expansion.

### **Advancements in Renal Replacement Therapies**

The US [Renal Disease Market](../../../reports/renal-disease-market-3167) industry has been significantly impacted by recent advancements in renal replacement therapies, notably dialysis and kidney transplantation. According to the United States Renal Data System, there were approximately 780,000 individuals undergoing dialysis or living with a functioning kidney transplant in the US as of 2020, and this number continues to rise as treatment methods improve.

With organizations like the American Society of Nephrology promoting Research and Development (R&D) in innovative dialysis technologies, such as portable dialysis machines, the market is set to benefit from increased patient accessibility and improved treatment efficacy, leading to an expansion in the patient base and subsequent market growth.

### **Government Initiatives and Funding for Renal Care**

The US government has taken substantial steps to improve renal care through policy initiatives and funding opportunities. For instance, programs like the End-Stage Renal Disease (ESRD) Quality Incentive Program aim to enhance the quality of care for patients requiring dialysis treatment. According to the Centers for Medicare & Medicaid Services, government expenditures on renal healthcare surpassed $33 billion in 2020, a figure projected to grow as the population ages and chronic conditions become more prevalent.

Such funding directly impacts the US Renal Disease Market industry by ensuring financial support for healthcare providers and enabling them to invest in new technologies and improved patient care methods.

## **US Renal Disease Market Segment Insights**

### **Renal Disease Market Type Insights**

The US Renal Disease Market encompasses a diverse landscape shaped by various types, primarily focusing on Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD). Chronic Kidney Disease remains a profound concern in the US, substantially impacting millions of individuals, leading to its classification as a critical public health challenge. The prevalence of CKD has been on the rise due to factors such as diabetes and hypertension, necessitating enhanced management and treatment options to support patients throughout their disease trajectory.

The US Renal Disease Market statistics show a significant portion of healthcare spending directed towards CKD management, reflecting its economic burden on the healthcare system. End-Stage Renal Disease is particularly critical as it represents the advanced stage of kidney disease where patients typically require interventions such as dialysis or kidney transplantation to extend their lives. This condition is associated with a host of complications, further driving demand for specialized healthcare services and advanced therapies.

The growing aging population in the United States contributes to the rising prevalence of ESRD, as older adults are more susceptible to kidney-related ailments, thus amplifying the opportunities within the market. The market growth surrounding these types is driven by increasing awareness about kidney health, along with advances in medical technology that facilitate better diagnosis and treatment options. There is also a noteworthy push towards preventive healthcare, aiming to reduce the burden of chronic diseases, including CKD.

With a significant investment in research and development, institutions are increasingly focusing on innovative therapies and patient-centric care approaches to mitigate the progression of kidney disease and enhance the quality of life for affected individuals. Opportunities also arise from ongoing initiatives encouraging routine screening and early detection of renal diseases, crucial for managing CKD effectively and potentially averting ESRD. However, challenges persist, such as disparities in access to care and socioeconomic factors influencing patient outcomes.

Improving healthcare policies, fostering education on kidney diseases, and ensuring equitable access to treatment and preventive measures are essential steps to address these challenges within the US Renal Disease Market. The segmentation of the US Renal Disease Market highlights the overarching importance of Type segmentation in elucidating treatment pathways and healthcare strategies focused on managing renal diseases. By concentrating resources and efforts on both Chronic Kidney Disease and End-Stage Renal Disease, stakeholders can optimize patient care and resource allocation, thereby contributing to improved overall health outcomes in the US population.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Renal Disease Market Treatment Insights**

The Treatment segment of the US Renal Disease Market encompasses critical methods that address kidney-related health issues among patients. This segment is characterized by key approaches including Dialysis, Medication, and Kidney Transplantation. Dialysis remains a predominant option due to the growing prevalence of chronic kidney disease, necessitating life-sustaining treatment for many individuals.

Medication plays a vital role in managing various conditions associated with renal diseases, such as hypertension and anemia, and is essential for improving patients' quality of life. Additionally, Kidney Transplantation stands out as a long-term treatment solution that can significantly enhance survival rates and reduce healthcare costs associated with ongoing dialysis.

The US Renal Disease Market presents opportunities driven by advancements in technology, increased healthcare expenditures, and rising awareness regarding kidney health. However, challenges such as the high costs of treatments and limited availability of donor organs for transplantation persist. Valuable insights from the US Renal Disease Market data emphasize the dynamic nature of treatment options available and their potential impact on patient outcomes as healthcare providers adapt to evolving patient needs and technological advancements in renal care.

As the market develops, ongoing Research and Development initiatives are expected to foster innovation in treatment methodologies, ultimately benefiting those affected by renal diseases.

### **Renal Disease Market End User Insights**

The US Renal Disease Market reflects significant growth driven by a diverse array of end users, primarily including Dialysis Centers, Hospitals and Clinics, as well as Research and Academic Institutes. Dialysis Centers play a crucial role in providing specialized care for patients with renal disease, making them a dominant force in patient treatment and management. The increasing prevalence of chronic kidney conditions enhances the reliance on these centers for effective management and treatment.

Hospitals and Clinics also serve as critical access points for patients seeking multidisciplinary care, contributing significantly to market dynamics by facilitating comprehensive treatment plans and patient monitoring. Research and Academic Institutes are essential for advancing the understanding of renal diseases, driving innovation, and developing new treatment modalities, which contributes to market growth.

The overall emphasis on improving patient outcomes and fostering research initiatives positions the end user segment as a vital component in the US Renal Disease Market, sustaining the momentum of advancements and care methodologies. As the market evolves, the integration of technology in these environments holds promise for enhancing efficiency and improving patient management in the realm of renal diseases.

## **US Renal Disease Market Key Players and Competitive Insights**

The US Renal Disease Market is a critical sector that addresses the increasing prevalence of kidney-related ailments, particularly chronic kidney disease and end-stage renal disease. As the demand for renal therapies and interventions rises, the competitive landscape is shaped by various players ranging from biotechnology firms to dialysis service providers. The market is characterized by innovations in treatment options, including pharmacological therapies, and improvements in dialysis technologies.

Research and development efforts have intensified, driving the emergence of novel therapies aimed at better patient outcomes and enhanced quality of life for individuals suffering from renal diseases. Market players are continually exploring strategic collaborations, partnerships, and acquisitions to strengthen their market positions while navigating regulatory challenges and the need for cost-effective solutions.

NantKwest has carved out a notable presence in the US Renal Disease Market with its focus on immunotherapy products and its innovative approach towards kidney diseases. The company's strengths lie in its dedication to research and development, which allows it to remain at the forefront of advancing treatment options. NantKwest's robust pipeline of investigational therapies demonstrates potential efficacy in renal-related conditions, creating optimistic prospects for patients who have limited options.

The integration of cutting-edge technology and a strong emphasis on clinical trials augment its position, allowing it to leverage competitive advantages in a market that is constantly evolving. Furthermore, NantKwest’s commitment to forging partnerships enhances its capabilities and reach, ultimately aiming to deliver transformative treatments within the renal disease sector.

American Renal Associates stands out in the US Renal Disease Market with a prominent focus on providing high-quality dialysis services. The company operates a substantial network of outpatient dialysis facilities across the country, delivering essential care to patients with chronic kidney disease. American Renal Associates focuses on personalized patient care and builds strong relationships with their dialysis patients, contributing to superior patient satisfaction and adherence to treatment protocols.

Key services include in-center hemodialysis, home dialysis, and related renal services. The company has also pursued strategic growth through mergers and acquisitions, enabling it to expand its facility footprint and enhance operational efficiencies. With a commitment to improving patient outcomes, American Renal Associates continues to leverage its extensive market presence and specialized expertise to solidify its leadership position in this crucial segment of the healthcare landscape.

### **Key Companies in the US Renal Disease Market Include**

### **US Renal Disease Market Industry Developments**

Recent developments in the US Renal Disease Market have set a dynamic tone for the sector, with significant initiatives and advancements. For instance, in August 2023, DaVita Inc announced a partnership with Fresenius Medical Care to enhance patient care. The collaboration aims at integrating innovative treatment modalities and improving patient outcomes.

Furthermore, in July 2023, American Renal Associates reported a notable increase in its quarterly earnings and projected growth, demonstrating a strengthening financial position within the market. Additionally, U.S. Renal Care has been expanding its facilities and services throughout various states, highlighting a growing demand for renal care services.

In the context of mergers and acquisitions, Otsuka Pharmaceutical completed the acquisition of Keryx Biopharma in September 2023, which adds valuable assets to their portfolio focused on renal solutions. Over the past two years, companies such as Baxter International and AbbVie have invested heavily in Research and Development to innovate treatments for renal disease, particularly considering the rise in diabetes-related kidney conditions in the US.

With a projected valuation growth, the US Renal Disease Market is increasingly robust, driven by evolving treatment protocols and enhanced collaborations among leading companies.

## **US Renal Disease Market Segmentation Insights**

### **Renal Disease Market Type Outlook**

### **Renal Disease Market Treatment Outlook**

### **Renal Disease Market End User Outlook**

## Market Drivers

### Increasing Aging Population

The aging population in the United States is a critical driver of the renal disease market. As individuals age, the risk of developing chronic kidney disease (CKD) escalates significantly. Data indicates that approximately 37 million adults in the U.S. are affected by CKD, with the prevalence increasing among those aged 65 and older. This demographic shift suggests a growing demand for renal care services and treatments, thereby expanding the renal disease market. Furthermore, the aging population is likely to require more advanced therapeutic options, including dialysis and kidney transplants, which could further stimulate market growth. The renal disease market must adapt to these demographic changes by enhancing service delivery and developing innovative treatment modalities to cater to this vulnerable population.

### Rising Healthcare Expenditure

Healthcare expenditure in the United States continues to rise, which significantly impacts the renal disease market. In 2023, healthcare spending reached approximately $4.3 trillion, with a notable portion allocated to chronic disease management, including renal diseases. This increase in spending reflects a broader recognition of the importance of managing chronic conditions effectively. As healthcare providers and payers invest more in renal care, the market is likely to see enhanced access to treatments and technologies. Additionally, the focus on value-based care may drive innovations in the renal disease market, as stakeholders seek to improve patient outcomes while managing costs. This financial commitment could lead to the development of new therapies and improved patient management strategies.

### Growing Awareness and Education

Growing awareness and education regarding kidney health are pivotal drivers of the renal disease market. Public health campaigns and educational initiatives have increased knowledge about the risk factors and symptoms associated with kidney diseases. This heightened awareness encourages individuals to seek medical advice and undergo regular screenings, which can lead to earlier diagnosis and treatment. In the U.S., organizations dedicated to kidney health are actively promoting education on lifestyle modifications that can prevent renal diseases. As more individuals become informed about kidney health, the demand for renal care services is likely to rise, thereby benefiting the renal disease market. This trend underscores the importance of continuous education in fostering proactive health behaviors.

### Advancements in Diagnostic Technologies

Advancements in diagnostic technologies are transforming the renal disease market. Innovative tools such as point-of-care testing and advanced imaging techniques are enhancing the early detection and monitoring of kidney diseases. These technologies enable healthcare providers to identify renal issues at earlier stages, potentially improving patient outcomes. For instance, the introduction of non-invasive biomarkers has shown promise in diagnosing CKD more accurately. As these diagnostic tools become more widely adopted, the renal disease market is likely to experience growth driven by increased screening and early intervention. Moreover, the integration of artificial intelligence in diagnostics may further streamline processes, leading to more efficient patient management and treatment pathways.

### Regulatory Support for Innovative Therapies

Regulatory support for innovative therapies is a significant driver of the renal disease market. The U.S. Food and Drug Administration (FDA) has been increasingly focused on expediting the approval process for new renal treatments, including novel drugs and devices. This regulatory environment encourages pharmaceutical companies and biotech firms to invest in research and development for renal diseases. The introduction of breakthrough therapy designations and fast-track approvals has the potential to bring effective treatments to market more rapidly. As a result, the renal disease market may witness an influx of innovative therapies that address unmet medical needs, ultimately improving patient care and outcomes.

## Future Outlook

The [Renal Disease Market](https://www.marketresearchfuture.com/reports/renal-disease-market-3167) is projected to grow at a 9.72% CAGR from 2025 to 2035, driven by advancements in treatment technologies, increasing prevalence, and rising healthcare expenditures.

**New opportunities:**

- Development of telehealth platforms for remote patient monitoring Investment in AI-driven diagnostic tools for early detection Expansion of home dialysis solutions to enhance patient convenience

By 2035, the renal disease market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Chronic Kidney Disease (Largest) vs. End-Stage Renal Disease (Fastest-Growing)

Chronic Kidney Disease (CKD) remains the largest segment within the US renal disease market, accounting for a significant share of overall diagnosis and treatment options. The growing prevalence of risk factors such as diabetes and hypertension continues to escalate the number of CKD patients, leading to heightened demand for effective management strategies. On the other hand, End-Stage Renal Disease (ESRD) is rapidly emerging, driven by advancements in renal replacement therapies and increased awareness of treatment options available for patients. The focus on early detection and intervention is further propelling both segments into the spotlight.

The growth trend in CKD is predominantly influenced by an aging population and increased obesity-related complications. In contrast, the ESRD segment is experiencing vigorous growth due to improvements in dialysis and transplantation methods, making it a critical area of focus for healthcare providers. Continued research and innovation are essential to enhance patient outcomes in both CKD and ESRD, as healthcare systems aim to better manage the increasingly complex needs of this patient population.

Chronic Kidney Disease (Dominant) vs. End-Stage Renal Disease (Emerging)

Chronic Kidney Disease (CKD) stands as the dominant player in the renal disease market, primarily impacting a large segment of the adult population and linked to conditions such as hypertension and diabetes. It encompasses a broad range of stages, allowing for various treatment pathways, including lifestyle changes, medication, and potential transplantation. In contrast, End-Stage Renal Disease (ESRD) represents an emerging segment, characterized by its critical need for dialysis or transplantation when kidney function declines to a point of failure. The increasing prevalence of ESRD reflects unmet needs in CKD management, prompting healthcare innovators to develop more effective therapies, supportive care options, and educational resources focused on kidney health.

### By Treatment: Dialysis (Largest) vs. Kidney Transplantation (Fastest-Growing)

In the US renal disease market, the treatment segment is primarily dominated by dialysis, which accounts for the largest share among the available treatment options. Medication follows, catering to specific conditions associated with renal diseases, while kidney transplantation is emerging rapidly as a viable solution due to advancements in surgical techniques and post-operative care.

Growth trends indicate that the dialysis treatment is stable but saturated, lacking significant expansion potential. Conversely, kidney transplantation is witnessing a surge in popularity, driven by innovations in immunosuppressive therapies and improved donor-recipient matching processes. As the healthcare infrastructure continues to evolve, these factors are propelling the transplantation segment as a promising alternative for renal disease management.

Dialysis (Dominant) vs. Medication (Emerging)

Dialysis is the dominant treatment method within the renal disease segment, characterized by its established protocols and extensive healthcare support infrastructure. It provides essential renal replacement therapy for patients facing acute or chronic kidney failure. On the other hand, medication represents an emerging facet of renal disease treatment, focusing on managing co-morbidities and alleviating symptoms related to kidney dysfunction. As research progresses, new pharmaceutical options are being developed, offering hope for more effective management of renal conditions. The collaboration between healthcare providers and pharmaceutical companies is critical in enhancing treatment outcomes and expanding the therapeutic arsenal available to patients.

### By End User: Dialysis Centers (Largest) vs. Hospital & Clinics (Fastest-Growing)

In the US renal disease market, the distribution of market share among end users reveals that Dialysis Centers hold the largest segment share due to the increasing prevalence of chronic kidney diseases and the growing reliance on dialysis as a treatment option. Hospital & Clinics follow closely, serving as critical access points for patient care but with a smaller market share compared to Dialysis Centers. Research and Academic Institutes also contribute to the market, albeit to a lesser extent, focusing on innovation and research initiatives.

The growth trends in the segment are driven primarily by the rising incidence of renal diseases, coupled with advancements in dialysis technology that enhance patient outcomes. Dialysis Centers are seeing consistent demand as they become the preferred option for long-term therapy, while Hospital & Clinics are witnessing rapid adoption of new treatment protocols, making them the fastest-growing segment. The integration of telehealth services and outpatient care solutions further supports this trend, positioning both segments for continued growth over the coming years.

Dialysis Centers (Dominant) vs. Hospital & Clinics (Emerging)

Dialysis Centers are dominant in the US renal disease market, characterized by their specialized facilities dedicated solely to dialysis treatments. They provide comprehensive care that is crucial for patients requiring regular renal therapy, ensuring patient adherence through dedicated support staff and optimized equipment. In contrast, Hospital & Clinics represent an emerging segment, adapting to the growing needs of renal patients by incorporating specialized renal care teams and innovative treatment options. These institutions are increasingly equipped to handle outpatient dialysis, thus diversifying their service offerings. The collaborative approach between these segments aids in enhancing patient care, driving overall market growth.

## Competitive Benchmarking

The renal disease market in the US is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Fresenius Medical Care (DE), DaVita Inc (US), and Baxter International Inc (US) are actively pursuing strategies that enhance their operational capabilities and market presence. Fresenius Medical Care (DE) emphasizes innovation in dialysis technologies, while DaVita Inc (US) focuses on expanding its service offerings through strategic acquisitions and partnerships. Baxter International Inc (US) is enhancing its product portfolio with a focus on renal therapies, indicating a collective drive towards improving patient outcomes and operational efficiencies.The market structure appears moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is crucial in maintaining competitive pricing and ensuring product availability. The influence of major companies is significant, as their strategies not only shape their individual market positions but also impact the overall dynamics of the renal disease market.
In October DaVita Inc (US) announced a strategic partnership with a leading telehealth provider to enhance remote patient monitoring capabilities. This move is likely to improve patient engagement and adherence to treatment protocols, reflecting a broader trend towards digital health solutions in the renal space. Such partnerships may also facilitate better data collection and analysis, ultimately leading to improved patient outcomes.
In September Baxter International Inc (US) launched a new home dialysis system designed to increase patient autonomy and comfort. This innovation is significant as it aligns with the growing demand for home-based therapies, which are perceived as more convenient and less disruptive to patients' lives. The introduction of this system could potentially capture a larger share of the home dialysis market, which is expected to grow as more patients seek alternatives to in-center treatments.
In August Fresenius Medical Care (DE) expanded its operations in the US by opening a new manufacturing facility dedicated to producing advanced dialysis equipment. This expansion not only enhances their production capacity but also signifies a commitment to meeting the increasing demand for renal care solutions. The strategic importance of this facility lies in its potential to streamline supply chains and reduce lead times, thereby improving service delivery to healthcare providers.
As of November current trends in the renal disease market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are becoming increasingly vital, as companies recognize the need to collaborate in order to leverage technological advancements and enhance patient care. The competitive landscape is shifting from a focus on price-based competition to one that prioritizes innovation, technology, and supply chain reliability. This evolution suggests that companies that can effectively differentiate themselves through advanced solutions and strategic partnerships are likely to thrive in the future.

## Recent News & Developments

Recent developments in the US Renal Disease Market have set a dynamic tone for the sector, with significant initiatives and advancements. For instance, in August 2023, DaVita Inc announced a partnership with Fresenius Medical Care to enhance patient care. The collaboration aims at integrating innovative treatment modalities and improving patient outcomes.

Furthermore, in July 2023, American Renal Associates reported a notable increase in its quarterly earnings and projected growth, demonstrating a strengthening financial position within the market. Additionally, U.S. Renal Care has been expanding its facilities and services throughout various states, highlighting a growing demand for renal care services.

In the context of mergers and acquisitions, Otsuka Pharmaceutical completed the acquisition of Keryx Biopharma in September 2023, which adds valuable assets to their portfolio focused on renal solutions. Over the past two years, companies such as Baxter International and AbbVie have invested heavily in Research and Development to innovate treatments for renal disease, particularly considering the rise in diabetes-related kidney conditions in the US.

With a projected valuation growth, the US Renal Disease Market is increasingly robust, driven by evolving treatment protocols and enhanced collaborations among leading companies.

## Report Scope

| MARKET SIZE 2024 | 819.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 898.61(USD Million) |
| MARKET SIZE 2035 | 2272.16(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.72% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Fresenius Medical Care (DE), DaVita Inc (US), Baxter International Inc (US), AbbVie Inc (US), Amgen Inc (US), Novartis AG (CH), Sanofi (FR), Roche Holding AG (CH), Merck & Co Inc (US) |
| Segments Covered | Type, Treatment, End User |
| Key Market Opportunities | Advancements in personalized medicine and telehealth are transforming the renal disease market landscape. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the renal disease market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US renal disease market in 2024?**
A: The overall market valuation was $819.0 Million in 2024.

**Q: What is the projected market valuation for the US renal disease market by 2035?**
A: The projected valuation for 2035 is $2272.16 Million.

**Q: What is the expected CAGR for the US renal disease market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period is 9.72%.

**Q: Which companies are considered key players in the US renal disease market?**
A: Key players include Fresenius Medical Care, DaVita Inc, Baxter International Inc, AbbVie Inc, Amgen Inc, Novartis AG, Sanofi, Roche Holding AG, and Merck & Co Inc.

**Q: What were the market valuations for Chronic Kidney Disease and End-Stage Renal Disease in 2024?**
A: Chronic Kidney Disease was valued at $410.0 Million, while End-Stage Renal Disease was valued at $409.0 Million in 2024.

**Q: How do the treatment segments of Dialysis, Medication, and Kidney Transplantation compare in terms of market valuation?**
A: In 2024, Dialysis was valued at $300.0 Million, Medication at $350.0 Million, and Kidney Transplantation at $169.0 Million.

**Q: What are the projected market valuations for Dialysis Centers, Hospitals & Clinics, and Research and Academic Institutes by 2035?**
A: By 2035, Dialysis Centers are projected to reach $850.0 Million, Hospitals & Clinics $1000.0 Million, and Research and Academic Institutes $422.16 Million.

**Q: What segment is expected to dominate the US renal disease market in terms of treatment?**
A: The Medication segment is expected to dominate, with a projected valuation of $900.0 Million by 2035.

**Q: How does the market valuation for Dialysis Centers compare to that of Hospitals & Clinics in 2024?**
A: In 2024, Dialysis Centers were valued at $300.0 Million, whereas Hospitals & Clinics were valued at $350.0 Million.

**Q: What trends are anticipated in the US renal disease market as it approaches 2035?**
A: The market is likely to experience robust growth, driven by advancements in treatment options and an increasing patient population.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-renal-disease-market-20030*